You are here: Industry Insights > Novartis

News List

79 Employees Affected as Novartis Plans Shut Down of UK Site biospace
December 06, 2017
Despite support for proposed government investment in the pharma and biotech industries in the United Kingdom, Novartis is looking to close down a facility in Sittingbourne, England that could cost about 79 jobs.
Stellar results for Novartis, Teva anti-CGRP migraine drugs pharmatimes
December 01, 2017
Fifty percent of patients taking Novartis’ erenumab in a Phase III clinical trial had their migraine days cut by at least half, according to the data.
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania worldpharmanews
November 20, 2017
Novartis, the American Society for Clinical Pathology (ASCP) and the American Cancer Society (ACS) will work together to devise a common approach to improve access to cancer treatment in Sub-Saharan Africa.
NICE approves Novartis and Pfizer’s rival breast cancer drugs pharmafile
November 17, 2017
NICE has announced that it has given the nod to two new treatments for breast cancer with the approval of Pfizer’s Ibrance (palbociclib) and Novartis’ Kisqali (ribociclib).
Novartis looks past psoriasis for even bigger Cosentyx growth frontier fiercepharma
November 15, 2017
Novartis’ Cosentyx currently leads a crop of next-gen immunology products from a who’s who of Big Pharma. And the Swiss drugmaker intends to keep it that way.
Novartis targets specific patient population with strong Ilaris Phase 3 data pharmafile
November 15, 2017
Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific subgroup of the trial’s patient population – a subgroup which the Swiss drugmaker is now looking to target with the
Novartis, already up on CRISPR, CAR-T, looks to new gene editing R&D fiercebiotech
November 14, 2017
Novartis has penned a new deal with Homology Medicines as it looks to boost its already impressive R&D work in cell and gene therapy.
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people worldpharmanews
November 14, 2017
Novartis has announced new results from a real-world database study of patients in Germany prescribed Entresto® (sacubitril/valsartan) for heart failure with reduced ejection fraction (HFrEF).
Novartis ties with Royal Marsden to boost cancer care pharmatimes
November 10, 2017
Cancer patients living in North West and South West London are to benefit from a new Joint Working Project between Novartis and the Royal Marsden Partners Cancer Vanguard that aims to improve quality of care in the region by expanding the role of oncology
Novartis breast cancer medication Kisqali, struggling against Ibrance, finds niche in younger women fiercepharma
November 10, 2017
Novartis breast cancer medication Kisqali has struggled to gain traction in a field dominated by Pfizer blockbuster Ibrance. So it’s going where Ibrance hasn’t.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page